维普期刊资源整合服务平台（V6.5）

29篇 您的检索式：作者名="Messersmith W"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Compartmental control of mineral formation:adaptation of a biomineralization strategy for biomedical use显示文摘	Murphy W L Messersmith P B	2000	Polyhedron2000，19，3：	1
2	KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection显示文摘	JIMENO A MESSERSMITH W A HIRSCH F R	2009	J C/in Oncol2009，27，7：	1
3	Entrepreneurial orienta- tion and performance in young firms : The role of human resource management 显示文摘	Messersmith J G Wales W J	2013	International Small Business Journal2013，31，2：	1
4	Development of novel targeted agents in the treatment of metastatic colorectal cancer 显示文摘	Berge E Thompson C Messersmith W	2011	Clin Colorectal Cancer2011，10，4：	1
5	Current status of SRC inhibitors in solid tumor malignancies 显示文摘	Puls LN Eadens M Messersmith W	2011	Oncologist2011，16，5：	1
6	Oxaliplatin-induced neuropathy in colorectal cancer显示文摘	Weickhardt A Wells K Messersmith W		0，，：	1
7	A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 mono- clonal antibody, in combination with bevacizumab and paelitaxel in patients with advanced solid tumors 显示文摘	Patnaik A LoRusso P M Messersmith W A	2014	Cancer Chemother Phar- macol2014，73，5：	1
8	Promising targets and drugs in development for colorectal cancer 显示文摘	Thompson C Leong S Messersmith W	2011	Semin Oncol2011，38，4：	1
9	Entrepreneurial orienta- tion and performance in young firms: The role of hu- man resource management显示文摘	Messersmith J G Wales W J	2011	International Small Busi- ness Journal2011，31，2：	1
10	Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer显示文摘	Hochster HS Uboha N Messersmith W etal	2015	Cancer Chemother Pharmacol2015，75，1：	1
11	Targeting EGFR in Colorectal Cancer显示文摘	Messersmith W A	2008	N Engl J Med2008，359，17：	1
12	The de- velopment of regorafenib and its current and potential future role in cancer therapy显示文摘	Davis S L Eckhardt S G Messersmith W A etal	2013	Drugs Today2013，49，2：	1
13	Phase I study of R04929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors显示文摘	TOLCHER A W MESSERSMITH W A MIKULSKI S M	2012	J Clin Oncol2012，30，19：	1
14	Promising targets and drugs in development for colorectal cancer显示文摘	Thompson C Leong S Messersmith W	2011	Semin Oncol2011，38，4：	1
15	Binding of gefitinib,an inhibitor of epidermal growth factor receptor-tyrosine kinase,to plasma proteins and blood cells:in vitro and in cancer patients显示文摘	Jing L Brahmer J Messersmith W	2006	Invest New Drugs2006，24，4：	1
16	Integrating weed -feeding insects and herbicides for weed control 显示文摘	Messersmith C G Adkins S W	1995	Weed Technology1995，9，1：	1
17	KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection 显示文摘	Jimeno A Messersmith W A Hirsch FR	2009	J Clin Oncol2009，27，：	1
18	Mussel-inspired surface chemistry for multifunctionalcoatings显示文摘	LeeH Dellatore S M Miller W M Messersmith PB	2007	Science2007，318，：	1
19	Anti-Ma2 Paraneoplastic En- cephalitis in Association with Recurrent Cervical Cancer 显示文摘	Ney DE Messersmith W Behbakht K	2014	J Clin Neural2014，10，3：	1
20	Promising targets and drugs in development for eolorectal cancer显示文摘	Thompson C Leong S Messersmith W	2011	Sere Oncol2011，38，4：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示